trending Market Intelligence /marketintelligence/en/news-insights/trending/umvw752e6pnypzwohhqvra2 content esgSubNav
In This List

Lilly to acquire pain drug program from Hydra Biosciences

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


Lilly to acquire pain drug program from Hydra Biosciences

Eli Lilly and Co. will acquire a preclinical pain drug program from Hydra Biosciences Inc.

The Indianapolis-based company will acquire all assets related to Cambridge, Mass.-based Hydra's pre-clinical program related to the transient receptor potential ankyrin 1, or TRPA1, inhibiting drugs.

TRPA1 is a protein whose function includes an electrical signaling, among others, and is responsible for sensations of pain, pressure and warmth, among other things. Hydra's program is aimed at developing drugs that inhibit these proteins and act as a potential treatment of chronic pain syndromes.

Financial terms of the transaction were not disclosed.

Lilly said the transaction will have no change to its non-GAAP per share guidance for 2018.